Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2727Lung Neoplasms 944Small Cell Lung Carcinoma 447Neoplasms 419Colorectal Neoplasms 407Breast Neoplasms 355Melanoma 332Ovarian Neoplasms 316Neoplasm Metastasis 280Pancreatic Neoplasms 251Squamous Cell Carcinoma of Head and Neck 232Stomach Neoplasms 227Carcinoma, Renal Cell 214Triple Negative Breast Neoplasms 189Head and Neck Neoplasms 178Prostatic Neoplasms 152Esophageal Neoplasms 149Endometrial Neoplasms 145Uterine Cervical Neoplasms 139Urinary Bladder Neoplasms 132Mesothelioma 115Carcinoma 106Carcinoma, Hepatocellular 104Colonic Neoplasms 103Carcinoma, Transitional Cell 99Sarcoma 98Kidney Neoplasms 74Mesothelioma, Malignant 72Cholangiocarcinoma 67Liver Neoplasms 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × EGFRm Advanced Non-Small Cell Lung Cancer × Thoracic × Clear all
NCT06279728 2025-07-03

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Daiichi Sankyo

Approved for marketing
Thoracic

EGFRm Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡